Additional file 1: of Assessment of adverse events via a telephone consultation service for cancer patients receiving ambulatory chemotherapy KondoShunsuke ShibaSatoshi UdagawaRyoko RyushimaYasuaki YanoMiho UeharaTomoko AsanabeMihoko TamuraKenji HashimotoJun 2015 Figure S1. A) Common adverse events reported during consultation. B) Chemotherapy regimens of patients using the telephone consultation service. AC; adriamycin + cyclophosphamide, CBDCA; carboplatin, PTX; paclitaxel, GEM; gemcitabine, CEF; cyclophosphamide + epirubicine + 5-FU, CDDP; cisplatin, BV; bevacizumab.